Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer

February 4, 2026 updated by: Vakhtang Begiashvili, P. Herzen Moscow Oncology Research Institute

Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease.

NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy.

The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse.

The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management.

This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Gastric cancer remains one of the most important malignant tumors with significant geographical and regional differences in prevalence. Despite the decrease in the incidence of gastric cancer in advanced economies, this pathology still ranks fifth among patients with malignant neoplasms. As for cancer mortality rates, stomach cancer ranks third. Stomach cancer continues to be one of the most significant oncological diseases in the world, ranking fifth in terms of prevalence according to global statistics from GLOBOCAN 2022.

Modern medicine uses diagnostic technology - Next-generation sequencing (NGS), and biomarkers play an important role in the diagnosis, prognosis, and treatment of stomach cancer. These technologies provide a deep understanding of the molecular mechanisms underlying the disease and open up new possibilities for personalized therapy. NGS allows simultaneous analysis of multiple genes and detection of mutations, changes in gene expression and other genetic features. In the context of stomach cancer, next-generation sequencing allows for identification of mutations: Detection of specific mutations associated with stomach cancer can help determine prognosis and select appropriate treatment, study of the genomic profiles of patients: To identify potential targets for therapy, including immune and targeted drugs.

With the help of NGS and biomarkers, doctors can develop individualized treatment regimens for different age groups, which increases the effectiveness of therapy and reduces side effects. Biomarker analysis allows you to track the progression of cancer and identify patients with a high risk of recurrence. The study and determination of molecular genetic markers in tumor tissues, as well as the analysis of genetic and age-related factors influencing the development of gastric cancer, is an important scientific and clinical task. Solving this problem may allow us to develop a personalized approach to patient management.

This scientific paper will address the issue of the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations of various age groups in resectable gastric cancer.

Study Type

Observational

Enrollment (Actual)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Russia
      • Moscow, Russia
        • P.Herzen Moscow Oncological Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All consecutive patients with clinically documented primary gastric cancer undergoing elective surgery with curative intent

Description

Inclusion Criteria:

  • Patients with histologically confirmed diagnosis of gastric cancer
  • The resectable stage of the disease (I-III)
  • Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes
  • Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy
  • Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)

Exclusion Criteria:

  • The presence of metastases in distant organs at the time of diagnosis
  • Primary-multiple tumors
  • Diagnostic and palliative surgery
  • Incomplete clinical data
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Уoung-adult age group
age 18-44 yr.
Diagnostic test: Next-generation sequencing
Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena
Middle-aged group
age 45-59 yr.
Diagnostic test: Next-generation sequencing
Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena
Eldery age group
age 60-74 yr.
Diagnostic test: Next-generation sequencing
Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena
Senior age group
age > 75 yr.
Diagnostic test: Next-generation sequencing
Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Overall survival
Time Frame: 3 months
3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Mutational burden and genomic instability features assessed by NGS
Time Frame: 3 months
3 months
Spectrum of somatic mutations identified by NGS
Time Frame: 3 months
3 months
Disease free survival
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

P. Herzen Moscow Oncology Research Institute

Investigators

  • Study Director: Andrey Ryabov, MD, PhD, P.Herzen Moscow Oncological Research Institute
  • Principal Investigator: Vladimir Khomyakov, MD, PhD, P.Herzen Moscow Oncological Research Institute
  • Principal Investigator: Vakhtang Begiashvili, PhD student, P.Herzen Moscow Oncological Research Institute
  • Principal Investigator: Nadezhda Volchenko, MD, PhD, P.Herzen Moscow Oncological Research Institute
  • Principal Investigator: Shatalov Peter, PhD, P.Herzen Moscow Oncological Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2020

Primary Completion (Actual)

December 31, 2025

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

February 4, 2026

First Submitted That Met QC Criteria

February 4, 2026

First Posted (Actual)

February 11, 2026

Study Record Updates

Last Update Posted (Actual)

February 11, 2026

Last Update Submitted That Met QC Criteria

February 4, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 129

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Molecular Analysis

Clinical Trials on Next-generation sequencing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe